KD or its principal ketone body, 3-hydroxybutyrate (3HB), induced T cell-dependent tumor growth retardation in melanoma models and reestablished the therapeutic responses in conditions under which anti-PD-1 alone or in combination with anti-CTLA-4 failed to reduce tumor growth [51]. The gene discussed is CTLA4; the disease is neoplasm.